These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28077803)

  • 1. Gerosuppression by pan-mTOR inhibitors.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2016 Dec; 8(12):3535-3551. PubMed ID: 28077803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin, proliferation and geroconversion to senescence.
    Blagosklonny MV
    Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of replicative senescence by rapamycin in rodent embryonic cells.
    Pospelova TV; Leontieva OV; Bykova TV; Zubova SG; Pospelov VA; Blagosklonny MV
    Cell Cycle; 2012 Jun; 11(12):2402-7. PubMed ID: 22672902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From rapalogs to anti-aging formula.
    Blagosklonny MV
    Oncotarget; 2017 May; 8(22):35492-35507. PubMed ID: 28548953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect.
    Sousa-Victor P; García-Prat L; Muñoz-Cánoves P
    Oncotarget; 2015 Sep; 6(27):23052-4. PubMed ID: 26375366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell senescence, rapamycin and hyperfunction theory of aging.
    Blagosklonny MV
    Cell Cycle; 2022 Jul; 21(14):1456-1467. PubMed ID: 35358003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
    Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
    Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of phenotypes of cellular senescence by pan-mTOR inhibition.
    Walters HE; Deneka-Hannemann S; Cox LS
    Aging (Albany NY); 2016 Feb; 8(2):231-44. PubMed ID: 26851731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
    Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
    Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin and the inhibition of the secretory phenotype.
    Wang R; Sunchu B; Perez VI
    Exp Gerontol; 2017 Aug; 94():89-92. PubMed ID: 28167236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual response to mTOR inhibition in delaying replicative senescence of mesenchymal stromal cells.
    Antonioli E; Torres N; Ferretti M; Piccinato CA; Sertie AL
    PLoS One; 2019; 14(1):e0204784. PubMed ID: 30703123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
    Faes S; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Datta D; Demartines N; Dormond O
    Oncotarget; 2016 Jun; 7(24):36666-36680. PubMed ID: 27153561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2011 Nov; 3(11):1078-91. PubMed ID: 22156391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS.
    Huang H; Chen J; Lu H; Zhou M; Chai Z; Hu Y
    Biometals; 2017 Dec; 30(6):975-980. PubMed ID: 29063293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
    Feldman ME; Shokat KM
    Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.